A prospective analysis of red blood cell membrane polyunsaturated fatty acid levels and risk of non-Hodgkin lymphoma
AuthorsArdisson Korat, Andres V
Bertrand, Kimberly A
Epstein, Mara M
Rosner, Bernard A
Giovannucci, Edward L
Chavarro, Jorge E
Birmann, Brenda M
Document TypeJournal Article
KeywordsRed blood cell membrane fatty acids
polyunsaturated fatty acids
MetadataShow full item record
AbstractPublished studies report inconsistent associations of polyunsaturated fatty acid (PUFA) intake with non-Hodgkin lymphoma (NHL) risk. We conducted a nested case-control study in Nurses' Health Study and Health Professionals Follow-Up Study participants to evaluate a hypothesis of inverse association of pre-diagnosis red blood cell (RBC) membrane PUFA levels with risk of NHL endpoints. We confirmed 583 NHL cases and matched 583 controls by cohort/sex, age, race and blood draw date/time. We estimated odds ratios (OR) and 95% confidence intervals (CI) for risk of NHL endpoints using logistic regression. RBC PUFA levels were not associated with all NHL risk; cis 20:2n-6 was associated with follicular lymphoma risk (OR [95% CI] per one standard deviation increase: 1.35 [1.03-1.77]), and the omega-6/omega-3 PUFA ratio was associated with diffuse large B-cell lymphoma risk (2.33 [1.23-4.43]). Overall, PUFA did not demonstrate a role in NHL etiology; the two unexpected positive associations lack clear biologic explanations.
SourceArdisson Korat AV, Chiu YH, Bertrand KA, Zhang S, Epstein MM, Rosner BA, Chiuve S, Campos H, Giovannucci EL, Chavarro JE, Birmann BM. A prospective analysis of red blood cell membrane polyunsaturated fatty acid levels and risk of non-Hodgkin lymphoma. Leuk Lymphoma. 2022 Dec;63(14):3351-3361. doi: 10.1080/10428194.2022.2131419. Epub 2022 Oct 18. PMID: 36255154; PMCID: PMC9877158.
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/51639
Funding and AcknowledgementsThis work was supported by the [American Cancer Society] under [Research Scholar Grant RSG-11-020-01-CNE], by grants from the [National Institutes of Health] under grants [UM1 CA186107]; [P01 CA87969]; [R01 CA49449]; [U01 CA167552]; [R01 CA149445]; [R01 CA09812]; [U54 CA155626]; [P30 DK46200]; [KL2 TR001455 (to MME)], and [T32 CA009001 (to AVAK)] and the American Heart Association [grant 834106 to Y-HC].